EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Multicenter Real-World Evaluation of Intravitreal Bevacizumab, Aflibercept, and Ranibizumab for Diabetic Macular Edema

Efraim Berco, Orly Yakubovich Fink, Eilon Shcolnik, Michael Ostrovsky, Yuval Kozlov, Raman Tuli, Thomas Kin Man Lee, Ksenia Samocha, Shalhevet Goldfeather Ben Zaken, Nir Shoham-Hazon

Ophthalmologica · 2026-10-08 · 1-1

DOI: 10.1159/oph/aeeag015 ↗
AbstractBibliografische Angaben

Abstract

Introduction: Diabetic macular edema (DME) is a significant cause of vision loss in patients with diabetic retinopathy, and treatment outcomes in routine clinical practice may differ from those reported in randomized clinical trials. We assessed the real-world effectiveness and treatment patterns of intravitreal bevacizumab, aflibercept (2 mg), and ranibizumab in patients newly diagnosed with DME. Methods: A retrospective, multicenter observational study with a 1-year follow-up was conducted at public clinics in Israel and Canada. A total of 309 eyes from 277 treatment-naive patients with DME were analyzed, including both eyes from 32 patients. Eyes were grouped by the first-line therapy: bevacizumab (n = 199), aflibercept 2 mg (n = 63), or ranibizumab (n = 47). The primary endpoint was change in visual acuity (VA) at 1 year. Secondary endpoints included change in central retinal thickness (CRT), injection frequency, final injection interval, and treatment response metrics. Generalized estimating equation (GEE) models were used to account for inter-eye correlation. Results: At 12 months, VA improved by 6 ETDRS letters with no significant difference between groups in the primary endpoint (p = 0.501). In adjusted GEE analyses using bevacizumab as the reference group, aflibercept and ranibizumab were associated with greater CRT reduction (−60.31 µm and −57.24 µm, respectively), longer final injection intervals (+3.52 and +2.58 weeks), and fewer injections over 12 months (−2.05 and −2.21; all p < 0.001). Aflibercept was also associated with lower odds of nonresponse (OR 0.08, p = 0.010), and both aflibercept and ranibizumab were associated with lower odds of non-extension (OR 0.08 and OR 0.02, respectively; both p < 0.001). Conclusion: In this real-world multicenter cohort, VA improved after anti-VEGF treatment, without a significant between-group difference in the primary visual endpoint. Aflibercept (2 mg) was associated with more favorable secondary anatomical and treatment-burden metrics in adjusted analyses. However, given center-determined treatment allocation and residual baseline CRT imbalance, these findings should be interpreted as exploratory real-world associations rather than definitive evidence of pharmacological superiority. These results highlight the gap between randomized trial efficacy and outcomes observed in routine clinical practice, supporting the need for further practice-based DME research.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →